IP Library Assignment 061805/0076
Patent Assignment
Reel/Frame 061805/0076

Assignment of Assignor's Interest

Recorded: 2022-10-31 Pages: 27
Assignor
HORIZON PHARMA RHEUMATOLOGY LLC
Executed: 2020-03-31
Assignee
HORIZON THERAPEUTICS USA, INC
1 HORIZON WAY, DEERFIELD, ILLINOIS, 60015
Covered Properties (30)
Aggregate-Free Urate Oxidase for Preparation of Non-Immunogenic Polymer Conjugates
Patent: 6,783,965 →
Application: 09/501,730 →
Methods for Lowering Elevated Uric Acid Levels Using Intravenous Injections of Peg-Uricase
Patent: 8,148,123 →
Application: 11/539,475 →
Publication: US 2007/0274977
Purification of Proteins With Cationic Surfactant
Patent: 9,534,013 →
Application: 11/918,292 →
Publication: US 2009/0317889
Variant Form of Urate Oxidase and Use Thereof
Patent: 7,811,800 →
Application: 11/918,296 →
Publication: US 2009/0209021
Variant Forms of Urate Oxidase and Use Thereof
Patent: 8,188,224 →
Application: 11/918,297 →
Publication: US 2009/0169534
Variant Form of Urate Oxidase and Use Thereof
Patent: 7,964,381 →
Application: 12/879,084 →
Publication: US 2011/0104751
Variant Form of Urate Oxidase and Use Thereof
Patent: 8,034,594 →
Application: 13/107,498 →
Publication: US 2011/0217755
Variant Form of Urate Oxidase and Use Thereof
Patent: 8,178,334 →
Application: 13/226,891 →
Publication: US 2012/0070876
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Patent: 9,377,454 →
Application: 13/379,704 →
Publication: US 2012/0301454
Variant Form of Urate Oxidase and Use Thereof
Patent: 8,293,228 →
Application: 13/452,151 →
Publication: US 2012/0225046
Variant Forms of Urate Oxidase and Use Thereof
Patent: 8,541,205 →
Application: 13/461,170 →
Publication: US 2012/0309085
Variant Form of Urate Oxidase and Use Thereof
Patent: 8,465,735 →
Application: 13/623,512 →
Publication: US 2013/0084273
Variant Forms of Urate Oxidase and Use Thereof
Patent: 9,017,980 →
Application: 13/972,167 →
Publication: US 2013/0330803
Variant Forms of Urate Oxidase and Use Thereof
Patent: 9,670,467 →
Application: 14/671,246 →
Publication: US 2015/0197732
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Application: 15/165,318 →
Publication: US 2016/0377604
Variant Forms of Urate Oxidase and Use Thereof
Patent: 9,926,537 →
Application: 15/649,462 →
Publication: US 2017/0321193
Variant Forms of Urate Oxidase and Use Thereof
Application: 15/649,478 →
Publication: US 2017/0313994
Variant Forms of Urate Oxidase and Use Thereof
Patent: 9,926,538 →
Application: 15/649,488 →
Publication: US 2017/0313995
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Application: 15/906,839 →
Publication: US 2018/0188242
Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Application: 16/195,446 →
Publication: US 2019/0317083
Variant Forms of Urate Oxidase and Use Thereof
Application: 16/202,743 →
Publication: US 2019/0316097
Purification of Proteins with Cationic Surfactant
Application: 16/455,073 →
Publication: US 2020/0056160
Methods for Treating Gout
Application: 16/777,625 →
Publication: US 2020/0237879
Reducing Immunogenicity to Pegloticase
Application: 16/777,646 →
Publication: US 2020/0237881
Variant form of urate oxidase and use thereof
Application: 60/670,541 →
Reducing Immunogenicity to Pegloticase
Application: 62/855,519 →
Pegloticase for Treatment of Gout in Renal Transplant
Application: 62/894,452 →
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (Triple)
Application: 62/903,562 →
Reducing Immunogenicity to Pegloticase
Application: 62/903,567 →
Reducing Immunogenicity to Pegloticase
Application: 62/903,570 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 22, 2000
From: SHERMAN, MERRY R., PH.D.; SAIFER, MARK G.P., PH.D.; WILLIAMS, DAVID, PH.D.
To: MOUNTAIN VIEW PHARMACEUTICALS, INC.
Reel/Frame 010836/0572 →
Assignment of Assignor's Interest May 24, 2006
From: HERSHFIELD, MICHAEL S.; KELLY, SUSAN J.
To: DUKE UNIVERSITY
Reel/Frame 017663/0313 →
Assignment of Assignor's Interest Aug 28, 2007
From: REHRIG, CLAUDIA D.; HUANG, WILLIAM; HARTMAN, JACOB; MENDELOVITZ, SIMONA
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 019756/0045 →
Assignment of Assignor's Interest Jan 18, 2008
From: FISCHER, MEIR; HAROSH, ELIYAHU
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 020383/0946 →
Assignment of Assignor's Interest Jan 18, 2008
From: HARTMAN, JACOB; MENDELOVITZ, SIMONA
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 020386/0145 →
Assignment of Assignor's Interest Jan 18, 2008
From: HARTMAN, JACOB; MENDELOVITZ, SIMONA
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 020384/0974 →
Assignment of Assignor's Interest Jul 23, 2008
From: HERSHFIELD, MICHAEL S.
To: DUKE UNIVERSITY
Reel/Frame 021278/0683 →
Security Agreement Jun 12, 2012
From: SAVIENT PHARMACEUTICALS, INC.
To: MORGAN STANLEY SENIOR FUNDING INC.
Reel/Frame 028363/0040 →
Assignment of Assignor's Interest Aug 3, 2012
From: ROSARIO-JANSEN, THERESA; WRIGHT, DAVID ERICK
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 028715/0585 →
Corrective Assignment to Correct the Receiving Party Previously Recorded on Reel 028363 Frame 0040. Assignor(S) Hereby Confirms the Security Agreement. Jul 23, 2013
From: SAVIENT PHARMACEUTICALS, INC.
To: U.S. NATIONAL BANK ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 030936/0072 →
Security Agreement Feb 21, 2014
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 032319/0077 →
Security Agreement Mar 4, 2014
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 032384/0285 →
Assignment of Assignor's Interest Apr 15, 2014
From: SAVIENT PHARMACEUTICALS, INC.; SAVIENT PHARMA HOLDINGS, LLC
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 032675/0936 →
Security Interest Jul 21, 2015
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 036142/0931 →
Assignment of Assignor's Interest Aug 3, 2015
From: MOUNTAIN VIEW PHARMACEUTICALS, INC.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 036240/0827 →
Security Interest Aug 11, 2015
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 036300/0073 →
Assignment of Assignor's Interest Aug 18, 2015
From: SAVIENT PHARMACEUTICALS, INC.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 036388/0167 →
Release of Security Interest Jan 13, 2016
From: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0073 →
Release of Security Interest Jan 13, 2016
From: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0163 →
Release of Security Interest Jan 13, 2016
From: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0148 →
Release of Security Interest Jan 13, 2016
From: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0049 →
Change of Name Jul 5, 2016
From: CREALTA PHARMACEUTICALS LLC
To: HORIZON PHARMA USA RHEUMATOLOGY LLC
Reel/Frame 039258/0154 →
Change of Name Jul 5, 2016
From: HORIZON PHARMA USA RHEUMATOLOGY LLC
To: HORIZON PHARMA RHEUMATOLOGY LLC
Reel/Frame 039258/0152 →
Patent Security Agreement Sep 16, 2016
From: HORIZON PHARMA RHEUMATOLOGY LLC (FORMERLY KNOWN AS CREALTA PHARMACEUTICALS LLC)
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040059/0007 →
Change of Name Nov 18, 2016
From: CREALTA PHARMACEUTICALS LLC
To: HORIZON PHARMA USA RHEUMATOLOGY LLC
Reel/Frame 040648/0361 →